Michael Vlaicu
Articles by Michael Vlaicu
May 26, 2011
Optimer Pharmaceuticals is quickly approaching its May 30th PDUFA as as heavy favourite to win a positive vote from the FDA to market its product, yet it seems that many investors are discounting the potential for a surprise negative outcome. The company is trying to obtain approval for its flagship...
May 08, 2011
Atmel corporation looks poised for new 52-week highs
March 29, 2011
Medivation's stock rebounds in anticipation of phase III Alzheimer's disease clinical trial results.
March 27, 2011
Prostate cancer is the most common form of cancer among men, and two new companies in Medivation and Johnson & Johnson are leading the charge with their experimental new treatments. These two will highlight their findings at The American Society of Clinical Oncology (ASCO), a meeting which has quick...
March 24, 2011
An in-depth look at Optimer Pharma (NASDAQ:OPTR) and its potential buyout rumours for $19 a share.
Optimer Nears First Blockbuster Treatment For $7B CDI Market In 25 Years (NASDAQ:OPTR) (NASDAQ:CLDA)
March 22, 2011
Optimer pharmaceuticals prepares to enter the $7B CDI market with the first approved drug in over 25 years.
January 27, 2011
A small overview of potentially the first ever stem cell therapy to be approved by the FDA.
January 24, 2011
An idea of how you can hedge your portfolio against the upcoming market correction.
December 27, 2010
An in-depth analysis of the upcoming FDA catalysts for BioSante Pharmaceuticals.
December 23, 2010
Two companies that are bound for short squeezes: ATP Oil & Gas (NASDAQ:ATPG) and First Bankcorp (NYSE:FBP)
December 14, 2010
This article features the following companies: (NASDAQ:CLDA), (NYSE:PFE), (NYSE:LLY), (NYSE:MRK), (NYSE:KG), (NYSE:JNJ)
Something special is taking place in the next few weeks, a little known global biotechnology company in Clinical Data (NASDAQ:CLDA) is attempting to bring forth the first compou...
December 07, 2010
An in-depth analysis on VIVUS (NASDAQ:VIVUS)
June 19, 2010
The U.S. financial market rally is here to stay, or is it?
June 15, 2010
A closer look at the current US debt, recession, and how you can profit from it.
June 03, 2010
The Market Financial discusses the investment opportunity in Hana Biosciences (OTC:HNAB)
May 11, 2010
A a detailed investment report on Discovery Laboratories (NASDAQ:DSCO)
May 06, 2010
A fundamental and technical analysis of the market and price per share potential of AEterna Zentaris, (NASDAQ:AEZS)
May 04, 2010
Upcoming blockbuster drug that could redefine AEZS in the coming weeks, big FDA play.
May 02, 2010
Arrayit is expected FDA 510(k) submission of a game-changing Ovarian Cancer device, and the following article explains the potential.
April 30, 2010
Arrayit Corp (OTC:ARYC) could generate strong upward movement into the coming 510(k) New Medical Device submission, which could come at any point now.
April 26, 2010
AspenBio Pharma may be the target of a partnership or takeover in the coming months, and the following article discusses and disects whom those companies might be and why they chose Aspen.
April 22, 2010
An article which depicts the undervalued nature of AspenBio Pharma for investment purposes.
April 08, 2010
TheMarketFinancial.com analyzes Genta Incorporated and what the new year can bring to the table for them.
April 01, 2010
Shares of the company, Pacific Ethanol Inc. (NASDAQ:PEIX) rallied well over 20% on Thursday´s trading session in light of news that restructuring would cause them to once again re-enter a profitable state of operations. This investment opportunity couldn´t have come at a better time as analysts worldwide predict the Ethanol Market to double by 2012, representing a significant upside for production and marketing activities of Pacific Ethanol moving forward.
January 13, 2010
For more financial news visit, www.TheMarketFinancial.com
January 14, 2010
The Market Financial Analyzes Invo's Market Potential (OTC BB: IVOB)
December 02, 2009
Provision Interactive Brings 3D Tactile Holographic Advertising to the Market (OTC:PVHO.OB)
November 04, 2009
CardioCor Helping Americans Lose Weight Faster (PINK:CDOI.PK)
November 02, 2009
Pending IND Targetting a 28B AMD Market (OTC:ACTC.OB)
October 27, 2009
W2 Energy Redefines the Renewable Alternative Energy Industry (PINK:WTWO.PK)
October 22, 2009
A New Star Emerges in Diverse Media Group (PINK:DVME.PK)
October 20, 2009
XTend Medical Looks Towards Breakthrough Cancer Detection Nanotechology (PINK:XMDC.PK)
October 16, 2009
BizAuctions Looks to Rebound During Holiday Season (OTC:BZCN.OB)
October 14, 2009
News Awaits for AVAX's Phase II and Phase III Clinical Trials (OTC:AVXT.PK)
October 13, 2009
Paradigm Medical Rebounds as Investors Await Four New Devices (OTC:PDMI.PK)
October 08, 2009
Guided Therapeutics Targets One Billion Dollar Market (OTC:GTHP.OB)
October 07, 2009
Soligenix Aims for Bright Future Ahead (OTC:SNGX.OB)
October 02, 2009
FDA Play: Massive Potential, Undervalued, Gaining Momentum (OTC:SNGX.OB)
October 02, 2009
American Scientific Resources (PINK:ASFX.PK) Looks to Rise Up
September 30, 2009
NeoPharm Inc. (OTC:NEOL) Looks For Bright News in 4Q09
September 22, 2009
NDA Filing Nears for Biovest (OTC:BVTI)
September 18, 2009
LifeLine BioTechnologies Looks Ahead of FDA Decision (OTC:LLBO)
September 16, 2009
Provectus Takes Aim to Treat Five Types of Cancer (OTC:PVCT)
September 11, 2009
StocksHaven Investments profiles Nutra Pharma Inc.(OTC:NPHC)
September 13, 2009
StocksHaven Investments Profiles Imaging3's (OTC:IMGG) FDA Seeking Medical Device
September 09, 2009
StocksHaven Investments profiles GenVec and it's lead product TNFerade (NASDAQ:GNVC)
September 09, 2009
StocksHaven Investments Takes a Closer Look at Muscle Flex Inc. (OTC:MFLI)
September 04, 2009
Adeona Prepares Three Drugs for NDA Submission (AMEX:AEN)
September 01, 2009
Derma Sciences (OTC:DSCI) targets a prescription drug market that is 5x its present market cap
August 22, 2009
StocksHaven Investments takes a closer look at INVO BioScience Inc.
August 22, 2009
StocksHaven Investments profiles Biomoda Inc. (OTC:BMOD)
August 19, 2009
StocksHaven Investments Engagee in a Conversation with SymPowerco Corp CEO, John Davenport (PINK:SYMW)
August 18, 2009
StocksHaven Investments takes a closer look at the past performances in (OTC:SPNG), (NASDAQ:MESA), (AMEX:HEB), (OTC:ACCP), (OTC:NEPH), (OTC:BIEL), (NASDAQ:TESTR), (PINK:HTDS),(NASDAQ:SOMX),(PINK:SYMW)
August 05, 2009
StocksHaven Investments news portal takes a closer look at Javelin Pharmaceuticals (AMEX:JAV), which hopes its three drugs in Phase III, one of which already has European approval will make a splash within the pain medication market.
July 30, 2009
StocksHaven Investments news portal takes a closer look at SymPowerco Corp. (PINK:SYMW), which hopes its majority-owned subsidiary, Polygenic Power Systems alongside the recent government grant will propel it into future success.
July 22, 2009
StocksHaven Investments news portal takes a closer look at Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), which hopes its drug, Silenor will be approved for the treatment of insomnia.
July 21, 2009
StocksHaven Investments takes a look at Hard to Treat Diseases, Inc. (PINK:HTDS) which may profit from the upcoming flu season
July 15, 2009
The following article was written and contributed by a highly regarded investor and member within the StocksHaven Investments community, Jeff Lawson:
With the recent passage and signing of the Credit Card Accountability, Responsibility, and Disclosure Act of 2009 (the Credit CARD Act), some chang...
July 10, 2009
Shares of the neuroscience-based biotechnology company look to be at a favourable price point (NYSE:ELN)
July 08, 2009
Aradigm Corporation
(Public, OTC:ARDM)
Aradigm is a company with a lot of positive long-term gains, especially with regards to its product pipeline involving the inhaled Cipro product (ILCH) for BE and CF, however the short-term play is a very different story. This company lacks visibility and the ability to fully utilize press release syndication to maximize potential reach for investors, and also engages in massive dilution in order to maintain ongoing operations. Moreover, the financial position also suffers as the company is enduring a heavy amount of cash burn every year with zero revenues as of Q1 (Mar´09). There is also a big question mark when it comes to partnerships — who will step up to the plate and infuse the cash which is so badly sought after?
July 09, 2009
The Launching of TerreStar-1 Looks to Propel TerreStar Corp. (NASDAQ: TSTR) for Financial Success
July 05, 2009
StocksHaven Investments news portal takes a closer look at Access Pharmaceuticals (OTC:ACCP), which hopes its drug, MuGard will be a big hit in Europe.
June 19, 2009
StocksHaven Investments news portal takes a closer look at BioElectronics Corporation (OTC:BIEL), which hopes its drug, Allay (TM) - Menstrual Pain Therapy will turn the business' fortunes around and make way for a positive future ahead.
June 17, 2009
Nephros prepares for a year thats bound to feel like a roller coaster ride.
June 16, 2009
Novel Osteoarthritis Treatment by Nuvo (TSE:NRI) confident of FDA approval.
June 13, 2009
BioDelivery (NASDAQ:BDSI) Investors Confident Pre-FDA Announcement
June 10, 2009
StocksHaven Investments news portal takes a closer look at Access Pharmaceuticals (OTC:ACCP), which looks ahead for a very successful year with MuGard and their multi-national product distribution deals and partnerships.
Note: StocksHaven Investments is up 121% from the initial buy on May/8/09 of(AMEX:HEB)
June 07, 2009
StocksHaven Investments' reader analyzes and deciphers the latest information on Hemispherx (AMEX:HEB) Ampligen
June 03, 2009
StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), and its drug Ampligen which is used as an adjuvant to combat H5N1 (Swine Flu)
June 02, 2009
StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), and analyzes the potential PPS should Ampligen see FDA approval in the coming weeks.
June 01, 2009
StocksHaven Investments news portal takes a closer look at the Consumer Confidence Index as of May 2009, which displays high optimism towards a faster than expected economic recovery.
Articles by Michael Vlaicu From Other Sources
July 22, 2009
published in Second Time´s a Charm for Somaxon (NASDAQ:SOMX)